Fenwick Represents Pharmakon in Definitive Senior Secured Loan Agreement for Reata Pharmaceuticals

Fenwick represented Pharmakon, an investor in non-dilutive debt for the life sciences industry and the investment manager of the BioPharma Credit funds, in IP diligence regarding a definitive senior secured loan agreement for up to $275 million (in two parallel $137.5 million investments) for Reata Pharmaceuticals (NASDAQ: RETA), a global biopharmaceutical company focused on developing and commercializing novel therapies for patients with severe diseases. On February 28, 2023, Reata received approval in the US for SKYCLARYS (omaveloxolone), the first approved medication indicated for the treatment of Friedreich’s ataxia, a rare genetic disease affecting the nervous system in adults and adolescents aged 16 years and older.

More information can be obtained from the news article.

The Fenwick team included intellectual property partner Dr. Carl Morales and senior associate Dr. Glenn Foulds and corporate partner Eric Shedlosky.